Texas A&M Health Science Center
Contact Info:
Clifford Stephan
2121 W. Holcombe Blvd
Institute of Biosciences and Technology
Houston, TX 77030
https://ibt.tamu.edu/centers/translational-cancer-research/stephan-lab/folder/index.html
Grants and Identifiers:
RRID: RRID:SCR_023717
Instrumentation:
Formulatrix Mantis Automated Liquid Handler
Automated liquid handler with a diaphragm-based chip design that dispenses aqueous and organic solutions. It will dispense in any SBS template from 6 to 1536 well plates, and can be easily programmed to dispense to custom designs as needed. [Product Link]
cite this instrument
Molecular Devices ImageXpress High Content Confocal Imaging System
ImageXpress Micro Confocal system is a high-content solution that can switch between widefield and confocal imaging of fixed and live cells. It can capture high quality images of whole organisms, thick tissues, 2D and 3D models, and cellular or intracellular events. The spinning disc confocal and sCMOS camera enable imaging of fast and rare events like cardiac cell beating and stem cell differentiation. With MetaXpress software and flexible options like water immersion objectives to choose from, the system enables many confocal imaging applications from 3D assay development to screening. [Product Link]
cite this instrument
Services Provided:
Computational - Bioinformatics
Data Analysis And Interpretation
Small Molecule Compound Screening
Relevant Publications:
Description:
The Microphysiological Leads Optimization and Toxicity Screening facility (MLOTS) supports lead optimization programs and has established a roster of medium-throughput microphysiologic screening platforms including tissue- and tumor-on-a-chip platforms, organoid, and spheroid culture systems that will be used to evaluate the efficacy and toxicity of new lead compounds and drug combinations. The pharmaceutical industry has recognized the importance of implementing a “fail early” screening strategy early in the drug development process by adopting advanced physiological screening platforms and predictive in vitro toxicology testing. MLOTS supports a "fail early" approach as a lead optimization strategy by providing the resources to identify. toxic liabilities in lead series molecules before entering pre-clinical or clinical testing. MLOTS can evaluate NME for cardiovascular, neuro, or liver toxicity relative to reference standards using in vitro screening platforms.
